Key clinical point: In patients with psoriatic arthritis (PsA), 5 mg tofacitinib twice a day showed numerically better response with background ≥15 mg methotrexate per week. A twice daily dose of 10 mg tofacitinib, however, showed better response with background ≤15 mg methotrexate per week.
Major finding: In the 5 mg tofacitinib group, 51.4% vs. 47.4% of patients receiving background ≥15 mg methotrexate per week vs. ≤15 mg per week achieved American College of Rheumatology (ACR20) response at 3 months. However, in the 10 mg tofacitinib group, 54.9% vs. 51.8% of patients receiving ≤15 mg methotrexate per week vs. ≥15 mg per week achieved ACR20. No new safety risks were identified.
Disclosures: This study was funded by Pfizer. Some of the authors reported ties with various sources, including Pfizer. C Wang and L Takiya declared being employees and shareholders of Pfizer.